Delcath Systems

Youtube Subscribe

Open: 3.49 Close: 3.7 Change: 0.21

The best way to get information about Delcath Systems Stock: Use an AI.

This document will help you to evaluate Delcath Systems without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Delcath Systems are: Delcath, Systems, company, Chief, Medical, share, PM, …

Concept Map

Semantic Network

Stock Summary

Delcath Systems, Inc. focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. Its lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection.

Today's Summary

Chief Medical Officer Vojo Vukovic Acquires 40,000 shares of Delcath Systems. Chief Medical officer recently increased his stake in the company by purchasing 40,00 shares of the company. Delcath Systems, Inc. (DCTH) Latest Press Releases Follow $ 3.70 0.24 ( +6.94% ) 3:59 PM 12/19/23 NASDAQ | $USD | $ USD | Post-Market: $3.70 7:45 PM. Delcath Systems markets its products in the United States and Europe. Leading Bile Duct Neoplasm companies working in the market are Merck, AstraZeneca, Zymeworks, BeiGene, TransThera Sciences, and others.

Today's News

Chief Medical Officer Vojo Vukovic Acquires 40,000 shares of Delcath Systems. Chief Medical officer recently increased his stake in the company by purchasing 40,00 shares of the company. Delcath Systems, Inc. (DCTH) Latest Press Releases Follow $ 3.70 0.24 ( +6.94% ) 3:59 PM 12/19/23 NASDAQ | $USD | $ USD | Post-Market: $3.70 7:45 PM. Delcath Systems markets its products in the United States and Europe. Leading Bile Duct Neoplasm companies working in the market are Merck, AstraZeneca, Zymeworks, BeiGene, TransThera Sciences, and others.

Stock Profile

"Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York."

Keywords

How much time have you spent trying to decide whether investing in Delcath Systems? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Delcath Systems are: Delcath, Systems, company, Chief, Medical, share, PM, and the most common words in the summary are: follow, nasdaq, biotechnology, medical, pharmaceutical, therapeutic, c, . One of the sentences in the summary was: Leading Bile Duct Neoplasm companies working in the market are Merck, AstraZeneca, Zymeworks, BeiGene, TransThera Sciences, and others.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #follow #nasdaq #biotechnology #medical #pharmaceutical #therapeutic #c.

Read more →

Youtube Subscribe

---